NextFin News - The president’s announced plan for a 100% tariff on imported generic drugs is forcing Sandoz to consider a future it had been moving away from: making more medicines in the United States. Chief Executive Officer Richard Saynor says the policy is more opportunity than threat, but that optimism rests on a difficult trade. A two-year zero-tariff window gives manufacturers time to build a U.S. platform, while the announced 2028 and 2029 duties could make the existing global supply chain uneconomic. The question is whether tariffs create durable capacity or simply raise the cost of the medicines Americans use most.
President Donald Trump said imported generic drugs would remain subject to a 0% tariff from Aug. 1, 2026, for two years. He said the rate would then rise to 100% for one year beginning in August 2028 and to 200% thereafter. The timetable remains an announced policy plan rather than a final implementing rule. Its stated purpose is to reshore generic-pharmaceutical production, with a penalty for companies that do not build plants and equipment in the United States.
That gives Sandoz a policy window rather than an immediate customs shock. It also gives the company a strategic problem. Sandoz announced in February 2024 that it would close its Fougera manufacturing and packaging facilities in Melville and Hicksville, New York, with the process expected to conclude around the end of 2026. The facilities make dermatology products primarily for the U.S. market. A policy intended to pull production into America therefore arrives as Sandoz is completing a decision to reduce its American manufacturing footprint.
Sandoz’s North American sales were $2.1 billion in 2025, up 3% at constant currencies, compared with $5.0 billion in Europe, up 9%, and $2.5 billion in International markets, also up 9%, according to the company’s 2025 annual report. North America matters, but it is not the whole business. Sandoz reported 2025 net sales of $11.1 billion, while biosimilars grew 13%. The tariff question is less about protecting every dollar of current U.S. revenue than about deciding whether American manufacturing can become a competitive platform for a broader portfolio.
The first market verdict was negative. Sandoz shares fell about 3% after the July 22 announcement, with a separate public market summary reporting an intraday decline as large as 4.2%. Investors initially treated the proposal as a cost and execution risk. Saynor’s later assessment points to a different possibility: if the United States pays for resilient supply, companies with the scale, regulatory history and portfolio breadth to build locally could gain share. That is the opportunity. The policy risk remains the threat.
The Immediate Shock Is Deferred, Not Removed
The tariff plan changes Sandoz’s capital-allocation clock before it changes the reported income statement. The zero-duty period means there is no automatic 100% increase in landed cost in 2026 or 2027 under the president’s announcement. But the announced 2028 step-up falls within the investment horizon for a new manufacturing platform, because a generic-drug plant requires site selection, regulatory work, equipment, validation, hiring and customer commitments before it produces commercial volumes.
The pause also gives the administration bargaining power. Manufacturers can use it to seek exemptions, negotiate supply commitments or show that particular products cannot be moved economically. Policymakers can use the same period to test whether tariffs produce announced projects, domestic jobs and greater supply security. The timetable is therefore a negotiation mechanism as much as a tax schedule.
For Sandoz, the question is not simply whether an imported tablet would attract a 100% duty. Pharmaceutical supply chains separate active pharmaceutical ingredients, finished-dose production, packaging and distribution across countries. A company could localize one stage and still depend on foreign inputs. The eventual tariff’s practical effect will depend on the legal definition of an imported generic, the treatment of active ingredients and intermediates, and the criteria used to determine whether a manufacturer has built enough U.S. capacity.
That uncertainty matters because generic prices are not set like prices for a patent-protected medicine. Multiple manufacturers compete for contracts with wholesalers, pharmacies, hospitals and government programs. A producer that absorbs the tariff may lose margin; one that passes it through may lose volume; one that exits may leave a customer with fewer suppliers. The first transmission channel is therefore not a clean one-for-one price increase. It is a reallocation of capacity and bargaining power across manufacturers, buyers and patients.
“It’s more of an opportunity than a threat,” Sandoz Chief Executive Officer Richard Saynor said in an interview on Aug. 5, 2026.
Saynor also described Sandoz’s discussions with senior administration officials as “very, very constructive,” and said the company was discussing how to deliver high-quality, affordable medicines to American patients from European and U.S. platforms. The wording signals that Sandoz is seeking a policy solution that combines domestic production with its existing global network, rather than promising an immediate wholesale relocation.
The policy can force a decision without making domestic manufacturing profitable on its own. The FDA said in 2019 that Indian API manufacturing could reduce costs by an estimated 30% to 40% compared with U.S. and European production. A tariff may close part of that gap, but it does not remove the need for sufficient utilization, regulatory approval and a product portfolio with enough volume and margin to justify fixed costs.
The short-term conclusion is limited. The announced tariff plan is a deferred operating risk with an immediate strategic effect. The headline rate is visible today; the final cost depends on rules that have not yet been fully specified.
Why Sandoz Can See an Opportunity
The opportunity rests on scale and scarcity, not on tariffs improving the economics of every generic. Sandoz sells a broad global portfolio across Europe, North America and International markets. Its 2025 sales mix shows a company with enough geographic breadth to compare manufacturing platforms and enough U.S. exposure for Washington’s supply-security goals to matter. That gives Sandoz more options than a small manufacturer with one product and one factory.
Generic medicines sit at the center of the affordability debate. In 2024, generics accounted for 90% of U.S. prescriptions filled, or 3.9 billion prescriptions, but only 12% of prescription-drug spending, according to the Association for Accessible Medicines. Generic and biosimilar medicines generated an estimated $467 billion in savings for the U.S. health system that year. Those figures explain the political appeal of domestic production, but they also expose the constraint: a supply shock in generics reaches far more prescriptions than a comparable shock in branded drugs.
The FDA says greater generic competition can improve affordability and access. A domestic plant can therefore create strategic value if it reduces the chance of shortages, attracts more suppliers and gives hospitals or public purchasers confidence that essential medicines will remain available. A buyer may accept a higher manufacturing cost for a product that carries lower disruption risk. In that model, Sandoz is not competing only on the cheapest tablet. It is competing on continuity.
That is the second-order effect the initial share-price reaction may miss. Tariffs can raise Sandoz’s U.S. costs in the first instance, but they may also change what customers value. If procurement contracts begin to include domestic capacity, dual sourcing or minimum inventory requirements, a producer with a credible U.S. platform could gain negotiating leverage. The winner would not necessarily be the company with the lowest factory cost; it could be the company that meets a new definition of reliable supply.
The fixed-cost hurdle is high. Sandoz’s 2024 decision to close the Fougera sites shows that local production can be uneconomic even for a large global company. Those facilities specialize in dermatology products, and Sandoz said the closure was part of an optimization of its worldwide manufacturing network. The policy creates an incentive to reverse or replace that footprint, but a reversal would be expensive and would not necessarily restore the same products or jobs.
There is also an important difference between generics and biosimilars. Sandoz’s biosimilar business grew 13% in 2025, and biosimilars often involve more complex development, manufacturing and regulatory requirements than simple solid-dose generics. A U.S. platform built for complex products could support a higher-value portfolio and spread fixed costs across several categories. A plant built only to avoid duties on low-margin, high-volume tablets would face a more difficult return on capital.
The structural call is that the policy is a structural shift in supply-chain incentives, but not yet a structural shift in production itself. Rules and procurement preferences can change the industry’s investment map and may not reverse automatically. The cyclical part is the near-term reaction: share-price weakness, delayed projects and temporary inventory adjustments can mean-revert if exemptions or negotiated arrangements emerge. The regime effect becomes durable only when capital is committed, contracts are signed and validated capacity starts producing.
The opportunity is real but conditional. Sandoz can benefit from a higher value placed on local resilience; it cannot assume that every dollar of tariff exposure becomes a dollar of pricing power.
The Supply Chain Makes the Policy Harder Than the Slogan
The strongest case against Sandoz’s opportunity thesis is that tariffs can damage affordability before they create meaningful capacity. Generic competition depends on low manufacturing costs, and U.S. production cannot be built at scale simply by moving a packaging line. If duties apply broadly to finished drugs and inputs, manufacturers could face higher costs across the chain while patients and public purchasers absorb the increase.
FDA testimony illustrates why reshoring is difficult. In an August 2019 snapshot of API manufacturing sites serving the U.S. market, the United States accounted for 28%, the European Union 26%, India 18% and China 13%, with the remainder spread across Canada and other countries. Those historical shares are not a current market estimate, but they show how dependent the system was on a cross-border production network. The FDA’s 30% to 40% cost comparison shows why that network developed.
A tariff may therefore produce a perverse sequence. Importers raise prices or withdraw marginal products. Buyers consolidate orders with the few manufacturers that can absorb the cost. The market becomes less diversified before new domestic factories open. That can increase shortage risk, especially for medicines whose prices are already low enough that a new plant is hard to finance.
The counter-thesis attacks the central assumption behind the opportunity: that policy will reward capable incumbents rather than merely punish imports. Sandoz may have regulatory experience and a broad portfolio, but it still has to compete for construction capacity, skilled workers, permits and long-term customer contracts. Teva Pharmaceutical Industries and Viatris face similar incentives, while contract manufacturers may receive support through partnerships. The result could be a capital race that raises industry costs without producing enough excess capacity to improve reliability.
The policy also has a timing problem. The announced grace period runs through July 2028, but the Sandoz Long Island closure is expected around the end of 2026. The company must decide whether to preserve assets scheduled to leave the network, invest in a new site, contract with a U.S. producer or rely on imports while the rules are clarified. Each option has a different risk profile, and none is costless.
The strongest evidence for the positive thesis would be concrete: a final rule that defines domestic production clearly, preserves access to foreign APIs where no U.S. substitute exists, and attaches procurement or reimbursement benefits to validated U.S. capacity. The falsifying signal would be equally concrete. If the administration applies the 100% tariff broadly to finished drugs and key inputs without exemptions, and if Sandoz’s North American gross margin falls for two consecutive reporting periods after the duty begins, the opportunity thesis would be wrong for the operating business even if domestic capacity eventually grows.
The distinction between access and self-sufficiency matters. The United States can reduce dependence on a single foreign source without making every ingredient domestic. A diversified network with U.S. final-dose capacity, European backup production and multiple API suppliers may be more resilient than a politically attractive but economically narrow promise of total localization.
That is why the market’s first reaction was rational. Investors saw a measurable downside before they saw a contract, a subsidy or a plant. The opportunity case needs milestones.
What the Policy Means Across Time Horizons
In the short term, the tariff threat is a sentiment and execution risk for Sandoz and its peers. The July 22 share decline was about 3%, while a separate public market summary reported an intraday decline as large as 4.2%. The next catalysts are the legal text, the treatment of APIs and intermediates, and any exemptions or negotiated supply commitments. Until those details appear, equity volatility can remain higher than the eventual cash-flow impact warrants.
Over the medium term, the economics will be decided by portfolio mix and utilization. A company can spread a plant’s fixed cost across high-volume generics, injectables, dermatology products and biosimilars, but only if demand, pricing and regulatory approvals line up. Sandoz’s $2.1 billion North American revenue base gives it a meaningful customer platform, yet its 3% constant-currency growth in the region was slower than the 9% growth recorded in Europe and International markets in 2025. A domestic investment that merely protects existing sales may not be attractive; one that wins contracts and expands the portfolio could be.
Over the long term, the policy could change competitive structure. Domestic production might become a qualification for public procurement, an insurance premium paid through reimbursement, or a requirement attached to national-security medicines. If so, the industry will move from a pure cost hierarchy toward a two-dimensional market: manufacturing cost on one axis and supply assurance on the other. Sandoz’s global footprint would be useful in that market, but its earlier U.S. closures show that footprint alone does not guarantee returns.
The base case is a negotiated middle path. The zero-tariff window remains in place, the administration grants targeted flexibility for APIs and essential medicines, and Sandoz invests selectively in U.S. capacity tied to products where customer contracts can support utilization. In that scenario, near-term earnings pressure is manageable and the strategic value of domestic supply rises gradually.
The upside case requires a stronger trigger: U.S. buyers begin paying explicitly for domestic or dual-sourced supply, while Sandoz wins a portfolio of contracts large enough to justify a plant. That would turn tariff avoidance into a growth platform and could improve the company’s position relative to manufacturers with less capital or a narrower portfolio.
The downside case is a broad tariff with limited exemptions, followed by price controls or buyer resistance that prevents manufacturers from passing through the higher cost. Sandoz would then face the worst combination: capital spending to localize, lower margins on imported products and no assurance that domestic volumes earn an adequate return. A sustained decline in North American margin, product exits or new shortage notices would show that the policy is reducing access before it improves resilience.
For investors and policymakers, the key metric is not the tariff rate alone. It is the conversion rate from announced investment to validated, continuously supplied medicines. The administration wants factories; patients need dependable products; Sandoz needs returns that justify the factories. Those three tests will not be passed by the headline percentage.
Sandoz’s CEO is right that tariffs can become an opportunity, but only if Washington turns a penalty into a functioning market for resilience. Without that second step, the announced policy is more likely to reprice generic drugs than rebuild their supply chain.
Data cutoff: Aug. 5, 2026, 09:07 UTC.
Explore more exclusive insights at nextfin.ai.
